It appears no script is enabled within your browser. Please enable JavaScript to use this site.
Skip header and navigation
Home
View Selections:
0
Items
Help
Print
[2 significant stages in the management of mucoviscidosis: the French experience with dornase alfa (Pulmozyme) and the impact in international registries].
https://arctichealth.org/en/permalink/ahliterature204402
Source
Arch Pediatr. 1998 Apr;5(4):367-70
Publication Type
Article
Date
Apr-1998
More detail
Author
F. Brémont
J. Navarro
Source
Arch Pediatr. 1998 Apr;5(4):367-70
Date
Apr-1998
Language
French
Publication Type
Article
Keywords
Canada - epidemiology
Cystic Fibrosis - drug therapy - epidemiology
Deoxyribonuclease I - adverse effects - therapeutic use
Expectorants - adverse effects - therapeutic use
France - epidemiology
Humans
Italy - epidemiology
Recombinant Proteins - adverse effects - therapeutic use
Registries - statistics & numerical data
United States - epidemiology
PubMed ID
9759154
View in PubMed
Less detail
Permalink